All News

Cantwell discusses the importance of friends and family throughout the cancer journey.

A recent study identified the optimal time for certain patients with CML to stop TKI treatment.

A small, early trial demonstrated that a combination of Imlygic and Keytruda can have clinical benefit for patients with advanced melanoma.

Keytruda is showing promise for difficult-to-treat forms of head and neck cancer, according to two studies.

It is the people that make up a hospital, not the building.

With a cancer diagnosis, the conversations in your life often revolve around the topic of cancer. What about adding a little of the everyday, mundane stories back into your daily conversations?

A recent phase 1 study shows promise for the treatment of bladder cancer.

The combination of Opdivo and Yervoy showed promise for certain patients with colorectal cancer in a phase 2 study.

It took time to learn that protecting my kids from what I am going through also takes away my ability to support them.

Breast cancer, melanoma survivor and chemotherapy warrior is weary but she isn't ready to quit yet.

A phase 3 study showed improved survival rates for patients with high-risk, secondary AML who took Vyxeos.

Opdivo continues to demonstrate improved overall survival in lung cancer.

While the use of Kyprolis (carfilzomib), Pomalyst (pomalidomide) and KPd (dexamethasone) to treat some myeloma patients was "promising," researchers said that they will give the combination a closer look.

Temozolomide may have survival benefits for certain patients with brain cancer, according to a recent study.

On June 14, we'll be co-hosting a tweet chat with Oncology Nursing News to discuss key takeaways from the largest oncology meeting of the year.

The fight continues after remission. You simply begin to fight for more good days than bad instead of fighting for your life.

Tips on learning to move from cancer survivor to thriver.

Data from the KEYNOTE-087 study showed overall response rates of about 70 to 80 percent in three separate groups of relapsed/refractory Hodgkin lymphoma patients.

Alecensa may be the new first-line therapy for some patients with lung cancer, after a recent study yielded promising results for the drug.

Patients with relapsed serous ovarian cancer saw a survival benefit with Lynparza (olaparib) in a phase 2 trial.

While inherited factors do play a role in many people getting colorectal cancer, researchers are still unsure how to identify these mutations.

A large body of work has shown a clear benefit of exercise in reducing the risk of cancer and improving quality of life. But does perception of the exercise experience as enjoyable, or at least palatable, affect adherence or outcomes?

A phase 3 study showed that adding Ibrance to Femara reduces disease progression for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Previously treated patients with advanced renal cell carcinoma saw a higher overall survival rate with Cabometyx when compared to those on Afinitor, according to a phase 3 study.

A recent study explored six cancer-related dilemmas: understanding diagnosis; treatment planning; communication with the care team; finance and insurance issues; symptoms, side effects and quality of life; and survivorship.

When a loved one is diagnosed with cancer, the term "normal" has to be redefined.

Coming face-to-face with a cancer diagnosis not only shakes the very ground beneath one’s feet, it sends tremors throughout the mental landscape that constitute one’s worldview.

Avastin plus a novel antiangiogenic gene therapy resulted in significantly better overall survival for patients with recurrent glioblastoma multiforme.